We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Physician groups frustrated with federal plans to pair different biosimilar drugs together for billing and reimbursement purposes are turning to Congress for help. Read More
In anticipation of proposed guidance on biosimilar interchangeability, AbbVie is requesting that the FDA hold a hearing to ensure the agency considers all viewpoints. Read More
A law firm that represents drugmakers is urging the FDA to rethink its stance on granting meetings with senior agency officials, saying the existing policy can imperil drug research. Read More
The House Energy & Commerce Committee is calling on the GAO to evaluate whether the FDA’s regulatory pathway for generic versions of complex drugs is sufficient. Read More
Citing significant price increases for certain generic drugs, House Republicans have sent a
letter to Acting FDA Commissioner Stephen Ostroff with concerns about the agency’s process for approving ANDAs. Read More
The director of FDA’s CDER has laid out new priorities for the center to focus on in 2016, with negotiations for GDUFA and improvements at the Office of Generic Drugs among the center’s “front burner” priorities. Read More
Biosimilar labeling should piggyback on reference product labeling to bolster consumer confidence in this new class of medications, according to an FDA petition. Read More
Participants in a Dec. 9, 2015, Senate hearing — which addressed drug price manipulation of generics in uncontested markets — said the best way to stem the practice is to speed competitors to market and consider using compounders. Read More
The FDA’s first public meeting on the 2017 reauthorization of the Biosimilars User Fee Act brought calls for increased transparency in terms of how the agency regulates biosimilars and a rethinking of how these products will be named. Read More
Eleven healthcare groups are asking a Senate committee to examine alleged industry abuse of REMS safeguards as a possible cause of rising drug prices. Read More
A journal article asking the FDA to defy its own policies concerning mass compounding and drug importation to combat rising drug prices comes from an unusual source: the agency’s former second-in-command. Read More
The U.S. Department of Justice has filed an injunction to halt Dallas, Texas-based Downing Labs from manufacturing and distributing drugs until the compounder brings its operations into compliance with FDA regulations. Read More